Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-08
DOI
10.1038/s41598-019-56642-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System
- (2019) Ki Sun Jung et al. Clinical Lymphoma Myeloma & Leukemia
- Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
- (2018) Hsin-An Hou et al. Blood Cancer Journal
- Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
- (2018) Giulia Falconi et al. LEUKEMIA
- Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study
- (2017) Je-Hwan Lee et al. LEUKEMIA RESEARCH
- Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes
- (2016) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score
- (2015) Jose Falantes et al. LEUKEMIA RESEARCH
- A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
- (2015) Seong Hyun Jeong et al. Oncotarget
- Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
- (2014) C. Muller-Thomas et al. HAEMATOLOGICA
- Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
- (2014) Cecile Bally et al. LEUKEMIA RESEARCH
- Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome
- (2013) Je-Hwan Lee et al. ANNALS OF HEMATOLOGY
- How we treat lower-risk myelodysplastic syndromes
- (2013) P. Fenaux et al. BLOOD
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- (2013) Yun-Gyoo Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1-Risk Myelodysplastic Syndromes
- (2013) C. Fili et al. CLINICAL CANCER RESEARCH
- Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes
- (2013) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
- (2011) Sabine Hagemann et al. PLoS One
- Azacitidine for the treatment of lower risk myelodysplastic syndromes
- (2010) Pellegrino Musto et al. CANCER
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
- (2009) R. Gurion et al. HAEMATOLOGICA
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Myelodysplastic Syndromes
- (2009) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myelodysplastic syndromes
- (2008) S. D. Nimer BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now